These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

637 related items for PubMed ID: 3925239

  • 21. Evidence for a direct effect on vascular permeability of platelet-activating factor induced hemoconcentration in the guinea pig.
    Handley DA, Lee ML, Saunders RN.
    Thromb Haemost; 1985 Dec 17; 54(4):756-9. PubMed ID: 4089809
    [Abstract] [Full Text] [Related]

  • 22. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
    Tsunoda H, Sakuma Y, Harada K, Muramoto K, Katayama S, Horie T, Shimomura N, Clark R, Miyazawa S, Okano K.
    Arzneimittelforschung; 1990 Nov 17; 40(11):1201-5. PubMed ID: 2085331
    [Abstract] [Full Text] [Related]

  • 23. Cutaneous and pulmonary histopathological responses to platelet activating factor (Paf-acether) in the guinea-pig.
    Dewar A, Archer CB, Paul W, Page CP, MacDonald DM, Morley J.
    J Pathol; 1984 Sep 17; 144(1):25-34. PubMed ID: 6481526
    [Abstract] [Full Text] [Related]

  • 24. Production of platelet-activating factor in inflammatory exudate.
    Oh-ishi S, Imai Y, Hayashi M.
    J Lipid Mediat; 1992 Sep 17; 5(2):115-20. PubMed ID: 1525350
    [Abstract] [Full Text] [Related]

  • 25. Characterization of platelet-activating factor (PAF) receptor by specific binding of [3H]L-659,989, a PAF receptor antagonist, to rabbit platelet membranes: possible multiple conformational states of a single type of PAF receptors.
    Hwang SB, Lam MH, Hsu AH.
    Mol Pharmacol; 1989 Jan 17; 35(1):48-58. PubMed ID: 2536468
    [Abstract] [Full Text] [Related]

  • 26. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
    Nagaoka J, Harada K, Kimura A, Kobayashi S, Murakami M, Yoshimura T, Yamada K, Asano O, Katayama K, Yamatsu I.
    Arzneimittelforschung; 1991 Jul 17; 41(7):719-24. PubMed ID: 1663352
    [Abstract] [Full Text] [Related]

  • 27. Evidence that platelet activating factor may mediate some acute inflammatory responses. Studies with the platelet-activating factor antagonist, CV3988.
    Issekutz AC, Szpejda M.
    Lab Invest; 1986 Mar 17; 54(3):275-81. PubMed ID: 3951199
    [Abstract] [Full Text] [Related]

  • 28. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.
    Tahraoui L, Floch A, Mondot S, Cavero I.
    Mol Pharmacol; 1988 Aug 17; 34(2):145-51. PubMed ID: 2842653
    [Abstract] [Full Text] [Related]

  • 29. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
    Ring PC, Seldon PM, Barnes PJ, Giembycz MA.
    Mol Pharmacol; 1993 Feb 17; 43(2):302-12. PubMed ID: 8381515
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Inhibition of the platelet activating factor mediated component of guinea pig anaphylaxis by receptor antagonists.
    Darius H, Smith JB, Lefer AM.
    Int Arch Allergy Appl Immunol; 1986 Feb 17; 80(4):369-75. PubMed ID: 3015804
    [Abstract] [Full Text] [Related]

  • 32. Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues.
    Humphrey DM, McManus LM, Satouchi K, Hanahan DJ, Pinckard RN.
    Lab Invest; 1982 Apr 17; 46(4):422-7. PubMed ID: 7070056
    [Abstract] [Full Text] [Related]

  • 33. Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen.
    Woodward DF, Nieves AL, Spada CS, Williams LS, Tuckett RP.
    J Pharmacol Exp Ther; 1995 Feb 17; 272(2):758-65. PubMed ID: 7853191
    [Abstract] [Full Text] [Related]

  • 34. Platelet activating factor-induced microvascular permeability increases in the cat hindlimb.
    Lu Z, Wolf MB.
    Circ Shock; 1993 Sep 17; 41(1):8-18. PubMed ID: 8403248
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Species differences in platelet aggregation induced by platelet-activating factor (PAF).
    Shinozaki K, Kawasaki T, Kambayashi J, Sakon M, Shiba E, Ou M, Mori T.
    Methods Find Exp Clin Pharmacol; 1992 Nov 17; 14(9):663-5. PubMed ID: 1294855
    [Abstract] [Full Text] [Related]

  • 37. Trimucytin: a collagen-like aggregating inducer isolated from Trimeresurus mucrosquamatus snake venom.
    Teng CM, Ko FN, Tsai IH, Hung ML, Huang TF.
    Thromb Haemost; 1993 Mar 01; 69(3):286-92. PubMed ID: 8470053
    [Abstract] [Full Text] [Related]

  • 38. Release of platelet activating factor and its involvement in the first phase of carrageenin-induced rat foot edema.
    Hwang SB, Lam MH, Li CL, Shen TY.
    Eur J Pharmacol; 1986 Jan 14; 120(1):33-41. PubMed ID: 3948914
    [Abstract] [Full Text] [Related]

  • 39. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
    Komuro Y, Imanishi N, Uchida M, Morooka S.
    Mol Pharmacol; 1990 Sep 14; 38(3):378-84. PubMed ID: 2402227
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.